-
Je něco špatně v tomto záznamu ?
DNA vaccination against bcr-abl-positive cells in mice
V. Lučanský, E. Sobotková, R. Tachezy, M. Dušková, V. Vonka
Jazyk angličtina Země Řecko
Typ dokumentu práce podpořená grantem
Grantová podpora
NR9075
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Část
Zdroj
E-zdroje NLK
Free Medical Journals od 2006 do Před 1 rokem
Odkazy
Knihovny.cz E-zdroje
- MeSH
- bcr-abl fúzové proteiny genetika imunologie MeSH
- časové faktory MeSH
- chronická myeloidní leukemie genetika imunologie patologie prevence a kontrola MeSH
- DNA vakcíny genetika imunologie MeSH
- HL-60 buňky MeSH
- imunizace MeSH
- lidé MeSH
- mapování epitopu MeSH
- myši inbrední BALB C MeSH
- myši MeSH
- peptidové fragmenty imunologie MeSH
- protinádorové vakcíny genetika imunologie MeSH
- transfekce MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aabcr-abl did not induce significant protection. To localize the immunizing epitopes on the p210bcr-abl protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210bcr-abl protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
- 000
- 04059naa 2200493 a 4500
- 001
- bmc11022316
- 003
- CZ-PrNML
- 005
- 20140224140422.0
- 008
- 110729s2009 gr e Eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Lučanský, Vincent. $7 xx0306234
- 245 10
- $a DNA vaccination against bcr-abl-positive cells in mice / $c V. Lučanský, E. Sobotková, R. Tachezy, M. Dušková, V. Vonka
- 314 __
- $a Department of Experimental Virology, Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 520 9_
- $a A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12B1, which both expressed p210bcr-abl and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aabcr-abl did not induce significant protection. To localize the immunizing epitopes on the p210bcr-abl protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210bcr-abl protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové vakcíny $x genetika $x imunologie $7 D019496
- 650 _2
- $a mapování epitopu $7 D018604
- 650 _2
- $a bcr-abl fúzové proteiny $x genetika $x imunologie $7 D016044
- 650 _2
- $a HL-60 buňky $7 D018922
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunizace $7 D007114
- 650 _2
- $a chronická myeloidní leukemie $x genetika $x imunologie $x patologie $x prevence a kontrola $7 D015464
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední BALB C $7 D008807
- 650 _2
- $a peptidové fragmenty $x imunologie $7 D010446
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a transfekce $7 D014162
- 650 _2
- $a DNA vakcíny $x genetika $x imunologie $7 D019444
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sobotková, Eva $7 xx0103776
- 700 1_
- $a Tachezy, Ruth $7 xx0060363
- 700 1_
- $a Dušková, Martina $7 xx0127833
- 700 1_
- $a Vonka, Vladimír, $d 1930- $7 jk01150642
- 773 0_
- $t International Journal of Oncology $w MED00002350 $g Roč. 35, č. 4 (2009), s. 941-951
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110801130719 $b ABA008
- 991 __
- $a 20140224141233 $b ABA008
- 999 __
- $a ok $b bmc $g 881709 $s 732235
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00002350 $b 35 $c 4 $d 941-951 $m International journal of oncology $n Int J Oncol
- GRA __
- $a NR9075 $p MZ0
- LZP __
- $a 2011-4B09/jvme